INmune Bio (INMB) Competitors

$1.42 +0.01 (+0.35%)

As of 02:10 PM Eastern

INMB vs. HURA, SPRO, CRDL, ASRT, and EDSA

Should you buy INmune Bio stock or one of its competitors? MarketBeat compares INmune Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INmune Bio include TuHURA Biosciences (HURA), Spero Therapeutics (SPRO), Cardiol Therapeutics (CRDL), Assertio (ASRT), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry.

How does INmune Bio compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

TuHURA Biosciences has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 21.0% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

INmune Bio's return on equity of -103.03% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
INmune Bio	N/A	-103.03%	-77.66%

TuHURA Biosciences presently has a consensus target price of $9.00, suggesting a potential upside of 287.93%. INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 465.37%. Given INmune Bio's higher possible upside, analysts clearly believe INmune Bio is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

TuHURA Biosciences has higher earnings, but lower revenue than INmune Bio. TuHURA Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
INmune Bio	$50K	752.21	-$45.93M	-$1.67	N/A

In the previous week, TuHURA Biosciences had 2 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for TuHURA Biosciences and 2 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.20 beat TuHURA Biosciences' score of -0.75 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

INmune Bio beats TuHURA Biosciences on 10 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Spero Therapeutics?

INmune Bio (NASDAQ:INMB) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, INmune Bio had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Spero Therapeutics. INmune Bio's average media sentiment score of 0.20 beat Spero Therapeutics' score of -0.35 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 21.0% of INmune Bio shares are owned by company insiders. Comparatively, 5.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spero Therapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	752.21	-$45.93M	-$1.67	N/A
Spero Therapeutics	$66.80M	2.32	$8.57M	$0.24	11.15

Spero Therapeutics has a net margin of 24.90% compared to INmune Bio's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Spero Therapeutics	24.90%	35.58%	24.95%

INmune Bio has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

INmune Bio presently has a consensus target price of $8.00, suggesting a potential upside of 465.37%. Given INmune Bio's stronger consensus rating and higher probable upside, research analysts plainly believe INmune Bio is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Spero Therapeutics beats INmune Bio on 9 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

INmune Bio's return on equity of -103.03% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
INmune Bio	N/A	-103.03%	-77.66%

Cardiol Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 546.88%. INmune Bio has a consensus price target of $8.00, suggesting a potential upside of 465.37%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, Cardiol Therapeutics had 4 more articles in the media than INmune Bio. MarketBeat recorded 6 mentions for Cardiol Therapeutics and 2 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.20 beat Cardiol Therapeutics' score of -0.19 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 21.0% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Cardiol Therapeutics has higher earnings, but lower revenue than INmune Bio. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
INmune Bio	$50K	752.21	-$45.93M	-$1.67	N/A

Summary

INmune Bio beats Cardiol Therapeutics on 9 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Assertio?

Assertio (NASDAQ:ASRT) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

INmune Bio has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
INmune Bio	N/A	-103.03%	-77.66%

Assertio has higher revenue and earnings than INmune Bio. Assertio is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.27	-$30.38M	-$5.69	N/A
INmune Bio	$50K	752.21	-$45.93M	-$1.67	N/A

In the previous week, Assertio had 1 more articles in the media than INmune Bio. MarketBeat recorded 3 mentions for Assertio and 2 mentions for INmune Bio. Assertio's average media sentiment score of 0.39 beat INmune Bio's score of 0.20 indicating that Assertio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Assertio has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

49.0% of Assertio shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 5.7% of Assertio shares are held by insiders. Comparatively, 21.0% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Assertio presently has a consensus target price of $22.65, indicating a potential downside of 3.27%. INmune Bio has a consensus target price of $8.00, indicating a potential upside of 465.37%. Given INmune Bio's stronger consensus rating and higher possible upside, analysts plainly believe INmune Bio is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

Summary

INmune Bio beats Assertio on 10 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Edesa Biotech?

INmune Bio (NASDAQ:INMB) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 21.0% of INmune Bio shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

INmune Bio's return on equity of -103.03% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Edesa Biotech	N/A	-286.52%	-75.36%

INmune Bio has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Edesa Biotech has lower revenue, but higher earnings than INmune Bio. Edesa Biotech is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	752.21	-$45.93M	-$1.67	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

In the previous week, Edesa Biotech had 8 more articles in the media than INmune Bio. MarketBeat recorded 10 mentions for Edesa Biotech and 2 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.20 beat Edesa Biotech's score of -0.16 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

INmune Bio currently has a consensus target price of $8.00, indicating a potential upside of 465.37%. Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 54.00%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts plainly believe INmune Bio is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

INmune Bio beats Edesa Biotech on 8 of the 14 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.61M	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-0.85	18.89	20.88	25.51
Price / Sales	752.21	279.14	520.50	73.06
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	1.91	6.90	10.01	7.03
Net Income	-$45.93M	$24.18M	$3.54B	$334.92M
7 Day Performance	-15.77%	0.77%	0.38%	-0.40%
1 Month Performance	3.28%	-0.38%	-0.02%	1.07%
1 Year Performance	-81.03%	63.37%	35.07%	34.65%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	1.3729 of 5 stars	$1.42 +0.4%	$8.00 +465.4%	-81.6%	$37.61M	$50K	N/A	10
HURA TuHURA Biosciences	2.1382 of 5 stars	$2.40 +0.8%	$9.00 +275.0%	-35.8%	$151.56M	N/A	N/A	N/A	Earnings Report Gap Down
SPRO Spero Therapeutics	1.221 of 5 stars	$2.55 -0.4%	N/A	+286.7%	$148.23M	$66.80M	21.25	150	Gap Up
CRDL Cardiol Therapeutics	2.0853 of 5 stars	$1.34 +1.1%	$8.50 +536.7%	+16.1%	$147.60M	N/A	N/A	20
ASRT Assertio	2.0277 of 5 stars	$22.36 -0.6%	$19.90 -11.0%	+127.8%	$145.02M	$118.71M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. HURA, SPRO, CRDL, ASRT, and EDSA

How does INmune Bio compare to TuHURA Biosciences?

Summary

How does INmune Bio compare to Spero Therapeutics?

Summary

How does INmune Bio compare to Cardiol Therapeutics?

Summary

How does INmune Bio compare to Assertio?

Summary

How does INmune Bio compare to Edesa Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. HURA, SPRO, CRDL, ASRT, and EDSA

How does INmune Bio compare to TuHURA Biosciences?

Which has more risk & volatility, HURA or INMB?

Do insiders and institutionals hold more shares of HURA or INMB?

Is HURA or INMB more profitable?

Do analysts rate HURA or INMB?

Which has stronger valuation and earnings, HURA or INMB?

Does the media prefer HURA or INMB?

Summary

How does INmune Bio compare to Spero Therapeutics?

Does the media refer more to INMB or SPRO?

Do insiders and institutionals hold more shares of INMB or SPRO?

Which has better earnings & valuation, INMB or SPRO?

Is INMB or SPRO more profitable?

Which has more risk & volatility, INMB or SPRO?

Do analysts rate INMB or SPRO?

Summary

How does INmune Bio compare to Cardiol Therapeutics?

Is CRDL or INMB more profitable?

Do analysts rate CRDL or INMB?

Does the media refer more to CRDL or INMB?

Do insiders & institutionals hold more shares of CRDL or INMB?

Which has more volatility & risk, CRDL or INMB?

Which has preferable valuation & earnings, CRDL or INMB?

Summary

How does INmune Bio compare to Assertio?

Is ASRT or INMB more profitable?

Which has better earnings & valuation, ASRT or INMB?

Does the media prefer ASRT or INMB?

Which has more risk & volatility, ASRT or INMB?

Do institutionals and insiders hold more shares of ASRT or INMB?

Do analysts prefer ASRT or INMB?

Summary

How does INmune Bio compare to Edesa Biotech?

Do insiders & institutionals hold more shares of INMB or EDSA?

Is INMB or EDSA more profitable?

Which has more volatility and risk, INMB or EDSA?

Which has preferable valuation and earnings, INMB or EDSA?

Does the media prefer INMB or EDSA?

Do analysts prefer INMB or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools